1. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel
- Author
-
Samrat T. Kundu, Marta Boeke, Sunitha Nallur, Trupti Paranjape, Frank J. Slack, and Joanne B. Weidhaas
- Subjects
Colorectal cancer ,Gene Expression ,Single-nucleotide polymorphism ,Biology ,medicine.disease_cause ,Polymorphism, Single Nucleotide ,Epigenesis, Genetic ,Proto-Oncogene Proteins p21(ras) ,Open Reading Frames ,Breast cancer ,Cell Line, Tumor ,Proto-Oncogene Proteins ,microRNA ,medicine ,Humans ,Allele ,neoplasms ,Molecular Biology ,3' Untranslated Regions ,Alleles ,Genetics ,Mutation ,Binding Sites ,Cell Biology ,medicine.disease ,digestive system diseases ,Gene Expression Regulation, Neoplastic ,MicroRNAs ,Cancer research ,ras Proteins ,KRAS ,Ovarian cancer ,Developmental Biology - Abstract
The KRAS-variant is a germline single nucleotide polymorphism (SNP) within the 3'UTR of the KRAS gene predicted to disrupt a complementary binding site (LCS6) for the let-7 microRNA (miRNA). The KRAS-variant is associated with increased risk of various cancers, including lung cancer, ovarian cancer and triple-negative breast cancer, and is associated with altered tumor biology in head and neck cancer, colon cancer and melanoma. To better understand the molecular pathways that may be regulated or affected by the presence of the KRAS-variant allele in cancer cells, we examined its prevalence in the NCI-60 panel of cell lines and sought to identify common features of the cell lines that carry the variant allele. This study provides a step forward towards understanding the molecular and pathological significance of the KRAS-variant.
- Published
- 2011